ANI Pharmaceuticals, Inc.
ANIPStock
$81.92+23.56%52W
Market Cap$1.86B
P/E23.79x
Div yield—
Beta0.47
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-4.71%
Price vs S&P 500 (4W)-1.72%
VGM Score65.11
Market Capitalization$1.86B
P/E Ratio (Annual)23.79x
Earnings Surprise History
Q1 262.05est. 1.33
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.21
4.21
4.21
4.21
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANIPANI Pharmaceuticals, Inc. | C | A | C | $81.92 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
ANI Pharmaceuticals manufactures and markets generic prescription medications, specializing in narcotics, hormones, steroids, and complex formulations including extended-release and combination products. The company operates two business segments—Rare Diseases and Brands, Generics, and Others—with primary operations in the United States and a smaller Canadian presence.